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ABSTRACT
NRGN is the human homolog of the neuron-specific rat RC3/neu-
rogranin gene. This gene encodes a postsynaptic 78-amino acid pro-
tein kinase substrate that binds calmodulin in the absence of calcium,
and that has been implicated in dendritic spine formation and syn-
aptic plasticity. In the rat brain RC3 is under thyroid hormone control
in specific neuronal subsets in both developing and adult animals. To
evaluate whether the human gene is also a target of thyroid hormone
we have searched for T3-responsive elements in NRGN cloned
genomic fragments spanning the whole gene. Labeled DNA fragments
were incubated with T3 receptors (T3R) and 9-cis-retinoic acid recep-
tors and immunoprecipitated using an anti T3R antibody. A receptor-
binding site was localized in the first intron, 3000 bp downstream
from the origin of transcription. Footprinting analysis revealed the
sequence GGATTAAATGAGGTAA, closely related to the consensus
T3-responsive element of the direct repeat (DR4) type. This sequence
binds the T3R-9-cis-retinoic acid receptors heterodimers, but not T3R
monomers or homodimers, and is able to confer regulation by T3R and
T3 when fused upstream of the NRGN or thymidine kinase promoters.
The data reported in this work suggest that NRGN is a direct target
of thyroid hormone in human brain, and that control of expression of
this gene could underlay many of the consequences of hypothyroidism
on mental states during development as well as in adult subjects.
(Endocrinology 140: 335–343, 1999)
THE CALMODULIN-BINDING and protein kinase Csubstrate, RC31/neurogranin, is a member of a family
of proteins expressed in the central nervous system, for
which the term calpacitins has been recently proposed (1–3).
These proteins share many structural features, including a
calmodulin-binding domain, and are highly conserved
among species. RC3 is predominantly located in the soma,
dendrites, and dendritic spines of neuron subsets in the ce-
rebrum, and it is absent from the cerebellum (4–6). RC3
regulates the availability of free calmodulin in dendrites, a
function modulated by protein kinase C phosphorylation (7,
8). This is important because the concentration of activated
calmodulin in the postsynaptic cell is a function of free cal-
modulin and Ca21 ion concentrations, and determines the
activation of its distal targets, such as calmodulin kinase II,
adenylate cyclase, nitric oxide synthase, calcineurin, cyclic
nucleotide phosphodiesterase, etc. (7, 9, 10). Given these bio-
chemical properties, it has been suggested that RC3 plays a
role in dendritic spine formation, long term potentiation, and
synaptic plasticity (9–14).
RC3 expression is physiologically and developmentally
regulated. In rats, thyroid hormone (T3) is an important phys-
iological regulator (15, 16). Hypothyroid animals show re-
versibly decreased concentrations of RC3 messenger RNA
and protein in discrete areas of the forebrain. Regulation of
RC3 expression by thyroid hormone occurs in developing as
well as adult animals (17) and correlates to the known mor-
phogenetic actions of thyroid hormone on dendritic spines of
cerebral cortex and hippocampal neurons (18, 19). Regula-
tion by T3 occurs in other species besides the rat. Thus, the
goat RC3 homolog has also shown to be thyroid hormone
dependent in vivo (20). In addition, in mouse-derived hypo-
thalamic GT1–7 cells, thyroid hormone induces an increased
RC3 expression, which occurs at the transcriptional level and
is independent of new protein synthesis (21). RC3 regulation
by T3 is therefore presumably mediated through a direct
interaction of thyroid hormone receptors with regulatory
regions in the RC3 gene.
In brain as well as in other tissues, T3 acts in the cell nucleus
after binding to specific receptors. These receptors are mem-
bers of a large family of transcription factors that includes the
receptors for other hydrophobic ligands, such as retinoids,
steroid hormones, and other hormones or metabolites. They
control important developmental and physiological pro-
cesses by modulating the expression of genes after binding
to specific DNA sequences, known as response elements, that
are usually located in the upstream promoter region of the
target genes (22–24). Most of these nuclear receptors usually
bind to DNA as homodimers or heterodimers with the 9-cis-
retinoic acid receptor (RXR) (25). In the case of thyroid hor-
mone, the response elements, or T3REs, usually consist of a
direct repeat of the consensus hexamer sequence, AGGTCA,
Received May 8, 1998.
Address all correspondence and requests for reprints to: Dr. Juan
Bernal, Instituto de Investigaciones Biome´dicas, Arturo Duperier 4,
28029 Madrid, Spain. E-mail: jbernal@iib.uam.es.
* This work was supported by grants from Fundacio´n Ramon Areces
and DGICYT (PM95–0019).
† C.M.A. and B.M. contributed equally to this work.
‡ Predoctoral fellow supported by the Basque Government.
§ Postdoctoral fellow supported by the Community of Madrid.
1 In this article we refer to RC3 as the rat RC3/neurogranin gene, and
to NRGN as the human gene.
0013-7227/99/$03.00/0 Vol. 140, No. 1
Endocrinology Printed in U.S.A.
Copyright © 1999 by The Endocrine Society
335
 by on May 13, 2010 endo.endojournals.orgDownloaded from 
separated by four nucleotides (DR4), although other config-
urations are also relatively common (26, 27).
We have previously reported the identification, cloning,
and determination of the structure of the human RC3 ho-
molog gene, which we have named NRGN (28). The gene
spans 12 kb and contains four exons and three introns. Its
organization is identical to that of the rat Ng/RC3 gene, and
alignment of protein sequences revealed a 97.5% identity.
Besides characterization of the gene and chromosomal map-
ping, few data are available on NRGN expression in humans
(29). We have observed that its expression in the monkey
brain follows a pattern similar to that previously described
for the rat or goat brain (results to be published). This sug-
gests that NRGN could also be under thyroid hormone reg-
ulation in primates. To try to answer this question as well as
to disclose the mechanism of regulation by T3, we have
searched for T3REs in the human NRGN gene. Our previous
studies failed to disclose any such regulatory elements in the
59-flanking region of the rat or human genes (21, 28, 30). In
the present work we have used an immunoprecipitation
technique that allowed the screening of the whole gene. As
a result we report on the localization and characterization of
a T3RE in the first intron of the NRGN gene. The sequence
consists of a typical DR4, which binds the RXR-T3R het-
erodimer and is trans-activated in vitro by thyroid hormone
when fused to either the homologous promoter or to thy-
midine kinase promoter. The results provide an explanation
for T3 regulation. In addition, they suggest that, as previously
shown in the rat and goat, the NRGN gene is also under
thyroid hormone regulation, probably contributing to the
effects of this hormone on the development and function of
the human brain.
Materials and Methods
Plasmids and oligonucleotides
The following plasmids were used in this study: pBLCAT-2 a chlor-
amphenicol acetyltransferase (CAT) vector, in which the expression of
the reporter enzyme is under control of the thymidine kinase promoter;
thyroid hormone receptor (T3R) expression vector, consisting of the
complementary DNA encoding the rat T3Ra-1 cloned in pCDM8 (a gift
from Dr. P. R. Larsen, Brigham and Women’s Hospital, Boston, MA); and
retinoid X receptor expression vector, the human RXRa complementary
DNA, cloned in the plasmid pSG-5 (supplied by Dr. H. Stunnenberg,
University of Nijmegen, The Netherlands). The oligonucleotides used in
this study were synthesized as two complementary strands with 59-
extensions according to the sequence of the NRGN T3RE, as shown in
this paper, and the T3RE present in the long terminal repeat of the
Moloney murine leukemia virus (Mo) (31). The sequences of these nu-
cleotides were as follows (the DR4 half-sites are underlined): NRGN
T3RE, 59-TCGACTTCCAAAATGGGGATTAAATGAGGTAATATC 39;
and Mo T3RE, 59-TCGACAGGGTCATTTCAGGTCCTTGC-39.
The nonspecific oligonucleotide (NS) used for the gel retardation
experiments consisted of a 43-mer oligonucleotide corresponding to a
region of the promoter of rat proteolipid protein with the following
sequence:
59-GATCCAAGAGTTTGACTGGCTGATTTCCAGTTTGTG-39.
The mutated oligonucleotides of the NRGN T3RE were the following
(the nucleotide changes are underlined): M1, 59-TCGACTTCCAAAAT-
GGTTATTAAATGAGGTAATATC 39; M2, 59-TCGACTTCCAAAAT-
GGGGATTAAATGATTTAATATC 39; and M3, 59-TCGACTTC-
CAAAATGGGGATTACTTAAGGTAATATC 39.
The labeled DNA used in the footprinting assay was amplified using
the universal primer of the pMosblue vector (Amersham Pharmacia
Biotech, Rainham, Essex, UK) (240: 59-GTTTTCCCAGTCACGAC-39)
and the internal primer of the NRGN fragment (1588: 59-TGACT-
TTTCCTGCATTCAC-39).
For trans-activation experiments, a single copy of each of the follow-
ing oligonucleotides, NRGN T3RE, Mo T3RE, M1, M2, and M3, was
subcloned into the SalI site of pBLCAT-2 vector, which contains the CAT
gene under the control of the thymidine kinase promoter. In addition,
to evaluate the ability of the NRGN T3RE to regulate the activity of the
homologous promoter, the T3RE was inserted immediately upstream of
the NRGN promoter [nucleotides 2513 to 176 (28)] in the promoterless
pBLCAT-3 vector.
Transfection and CAT assays
COS-7 cells were grown and maintained in DMEM supplemented
with 10% FBS. The cells were plated to a density of 250,000 cells/6-cm
plate the day before transfection. The cells were transfected by the
calcium phosphate protocol (32), using 5 mg of the appropriate CAT
construct, 0.3 mg of the expression vector containing the nuclear recep-
tor, and 4 mg of the plasmid pCH110 (Amersham Pharmacia Biotech).
This plasmid contains the structural gene for b-galactosidase under
control of the simian virus 40 early promoter and was used as an internal
control of transfection efficiency. Sixteen to 18 h after DNA addition the
cells were washed with PBS and replenished with medium containing
serum depleted of thyroid hormones by treatment with Dowex resin.
Where appropriate, T3 (Sigma Chemical Co., St. Louis, MO) was added
to a concentration of 150 nm, and the cells were incubated for 24 h before
harvesting for determination of b-galactosidase and CAT activities (33).
Isolation of T3R-bound genomic DNA fragments
To isolate DNA fragments able to bind T3R we followed an immu-
noprecipitation method described previously (34). Plasmid clones span-
ning the whole NRGN gene (28) were cleaved with different restriction
enzymes, and all of the resulting fragments were end labeled with
Klenow DNA polymerase and [32P]deoxy-CTP. T3Rb1 and RXRa were
obtained by in vitro translation using the TNT kit (TNT Sp6 Coupled
Reticulocyte Lysate System, Promega Corp., Madison, WI). The reaction
mixture contained 105 cpm (4 3 107 cpm/mg) labeled DNA and 10–20
fmol of the in vitro translated T3Rb and RXRa in 40 ml binding buffer [25
mm HEPES (pH 7.9), 100 mm KCl, 1 mm dithiothreitol (DTT), 10%
glycerol, and 0,05 mg/ml poly(dI-dC)]. After incubation for 30 min at
room temperature, 500 ng anti-T3R antibody were added, and incuba-
tion was continued for 30 min at room temperature. To recover the
immunocomplexes, 20 ml 50% protein A-Sepharose, previously equili-
brated in binding buffer, were added and mixed during 20 min at room
temperature on a rotating wheel.
Protein A-Sepharose was washed three times with 500 ml washing
buffer [25 mm HEPES (pH 7.9), 100 mm KCl, 1 mm DTT, and 10%
glycerol], and the precipitated DNA fragments were eluted with 100 ml
1 m NaCl, extracted with phenol-chloroform, and precipitated with 100
ml isopropanol and 5 mg transfer RNA. The pellet was resuspended in
15 ml TE [10 mm Tris-HCl (pH 8) and 1 mm EDTA (pH 8)] and run on
a 1% agarose gel, which was then fixed in 10% trichloroacetic acid and
dried. The gel was exposed for 12 h at 270 C.
Footprinting assays
Deoxyribonuclease I (DNase I) footprinting assays were performed
with 3 ng (4 3 105 cpm) 32P-labeled, 260-bp BamHI-EcoRV immunopre-
cipitated fragment, subcloned in pMosblue. The labeled probe was ob-
tained by PCR amplification using the universal primer of the vector,
labeled at one end with T4 polynucleotide kinase, plus an unlabeled
internal primer of the fragment. The PCR conditions were: 5 min at 94
C; 35 cycles of 30 sec at 94 C, 30 sec at 55 C, and 1 min at 72 C; and 7
min at 72 C. Nuclear extracts from HeLa cells infected with vaccinia virus
expression vectors for the T3Ra and RXRa (a gift from Dr. H. Stunnen-
berg) were incubated in 40 ml binding buffer [25 mm HEPES (pH 7.9),
100 mm KCl, 1 mm DTT, 10% glycerol, and 0.05 mg/ml poly(dI-dC)].
After 5-min incubation at room temperature, the radioactive probe was
added and incubated for a further 30 min. Increasing amounts of DNase
I were then added, and incubation was continued for 1 additional min.
The reaction was terminated on ice by adding stop buffer (25 mm EDTA
and 1% SDS). Samples were extracted with phenol/chloroform and
ethanol precipitated. Pellets were resuspended in 6 ml water and 5 ml
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formamide loading buffer (80% formamide, 20 mm EDTA, 0.025% bro-
mophenol blue, and 0.025% xylene-cyanol) and boiled for 3 min before
loading on a 8% polyacrylamide-7 m urea sequencing gel. Electrophore-
sis was carried out at room temperature in 1 3 Tris-borate buffer (89 mm
Tris base, 88 mm boric acid, and 2 mm EDTA). As a control, 6 mg BSA,
instead of nuclear receptors, were used in parallel reactions.
Electrophoretic mobility shift assays (EMSA)
To study the interaction of T3R and RXR proteins with DNA, we used
in vitro translated nuclear receptors. Complementary oligonucleotides
were annealed, labeled with T4 polynucleotide kinase and [g-32P]ATP,
and purified with QIAquick Nucleotide Removal Kit (Qiagen, Chats-
worth, CA). The translated receptors were incubated in 13 ml binding
buffer [15% glycerol, 5 mm MgCl2, 50 mm KCl, 20 mm HEPES (pH 7.9),
5 mm DTT, and 0.3 mg/ml poly(dI-dC)] at room temperature. After 15
min, labeled probes (4 3 104 cpm) were added to the binding mixture,
and incubation was continued for 15 min. Competition gel-shift studies
were carried out by adding the indicated amounts of the competitor
oligonucleotide at the same time as the probe. The protein-DNA com-
plexes formed during binding reactions were separated on 6% poly-
acrylamide gels in 0.25 3 Tris-borate buffer at 250 V. The gels were dried
and exposed to films.
Supershift analysis was carried out by the addition of 1 ml of an
anti-T3R antibody to the gel shift reaction after the 30-min incubation.
The reaction mixture was incubated on ice for an additional 30 min and
then loaded on the gel.
For off-rate experiments, a 200-fold molar excess of unlabeled oligo-
nucleotides was added after the binding reaction. Samples were with-
drawn at intervals between 0–45 min and directly loaded on a running
gel. These experiments were performed in the presence of either 1 mm
EDTA or 1 mm MgCl2 in the binding buffer (35).
Results
Detection of a T3R binding site in the first intron of the
human neurogranin gene
Previous studies using genomic clones of the rat RC3 and
human NRGN genes failed to show the presence of T3REs in
the corresponding upstream promoter regions (28, 30). The
fact that T3 induces expression of RC3 at the transcriptional
level, both in vivo and in cultured cells (21, 36), and that the
effect on cultured cells was relatively fast and independent
of protein synthesis prompted us to analyze other regions of
the gene in search of putative T3RE sequences. The human
gene was used as starting material for these studies for two
reasons: firstly for convenience, because we had genomic
clones available from a previous study (28), and secondly for
biological relevance, because the presence of a T3RE would
strongly suggest that NRGN gene is also under T3 regulation.
We followed an immunoprecipitation technique to isolate
genomic fragments able to bind the T3 receptor protein (34).
NRGN genomic clones were cleaved by a set of restriction
enzymes, followed by end labeling of the resulting DNA
fragments. The labeled fragments were then used in coim-
munoprecipitation assays in an attempt to identify T3REs on
the basis of their expected interaction with the receptor. For
immunoprecipitations, we used a mixture of T3Rb and RXRa
proteins, previously obtained in vitro using a coupled tran-
scription and translation rabbit reticulocyte lysate system.
Control samples contained unprogrammed reticulocyte ly-
sate. The mixture of labeled DNA fragments was incubated
with either control or T3R/RXR-programmed lysate pro-
teins, and the resulting complexes were immunoprecipitated
with a specific anti-T3R antibody. Parallel incubations were
performed in the presence of an excess of a DR4 T3RE, like
the one present in the Moloney murine leukemia virus pro-
moter, to determine the absence of nonspecific binding to
DNA.
Figure 1A shows the structure of the human gene based on
the report by Martinez de Arrieta et al. (28). The gene contains
FIG. 1. Coimmunoprecipitation of
NRGN gene fragments with the T3R
protein. A, Map of NRGN. Exons are
represented as boxes, and the filled re-
gions of exons 1 and 2 correspond to the
coding sequences. The 1500 nucleotide
fragment (;3000–4500) bound in the
coimmunoprecipitation assays is shown
in expanded scale, and the restriction
sites are also indicated (B, BamHI; E,
EcoRI; RV, EcoRV; X, XbaI); the smaller
immunoprecipitated fragment is repre-
sented by the shaded area. B, The plas-
mid containing a 1.5-kb genomic frag-
ment of NRGN was digested with
XbaI1EcoRI and BamHI, and the re-
sulting fragments were end labeled
with Klenow enzyme. Lane D shows the
labeled fragments before the immuno-
precipitation assays. The fragments
were incubated with T3R/RXR proteins
(lane R) and were competed with a 200-
fold increase in unlabeled T3RE present
in the Moloney murine leukemia virus
(lane Mo). As a control, an incubation
with an unprogrammed reticulocyte ly-
sate (lane RL) was included. Complexes
were then precipitated with an anti-
T3R antibody bound to protein
A-Sepharose.
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four exons and three introns. Exon 1 encodes the 59-untrans-
lated region and the first five amino acids of the protein
sequence; the rest of the NRGN protein is encoded in exon
2. Exons 1 and 2 are interrupted by an intron of about 5 kb
long. In this work, we used several DNA fragments of sizes
up to 1.5 kb, encompassing the human gene from about 3 kb
upstream from the initiation of transcription to 0.5 kb down-
stream from the end of the fourth exon. All of these genomic
fragments were negative in the immunoprecipitation assays,
except for a 1.5-kb fragment of the first intron of the gene
from approximately nucleotide 3000–4500 (Fig. 1A) from the
origin of transcription. This fragment was cloned in pMos-
blue and subjected to further restriction digestion and im-
munoprecipitation analysis to more precisely delineate the
T3R-interacting region. Figure 1A shows a restriction enzyme
map, and Figure 1B shows the result of immunoprecipita-
tion. Digestion with XbaI plus EcoRI produced four frag-
ments: two of 0.1 kb, one of 1.4 kb, and one of 2.8 kb, the latter
containing the vector. The labeled fragments were resolved
in agar electrophoresis as three bands (Fig. 1B, lane D). After
incubation with T3R/RXR plus an anti-T3R antibody (lane R),
only the 1.4-kb band was precipitated. The specificity of this
effect was confirmed by performing a similar coimmuno-
precipitation experiment using as unlabeled competitor an
excess of the T3RE present in the Moloney murine leukemia
virus (lane Mo). In addition, the band was not observed if an
unprogrammed reticulocyte lysate (lane RL) was used. Di-
gestion with BamHI produced three bands, consisting of the
vector plus two bands of 0.9 and 0.6 kb, respectively. After
incubation with receptors and the anti-T3R antibody, only the
0.6-kb band was significantly immunoprecipitated. Further
digestion and immunoprecipitation of smaller fragments
(not shown) narrowed the size range of the DNA able to bind
T3R/RXR to a 260-bp BamHI-EcoRV fragment derived from
the 59-portion of the original fragment.
These results strongly suggested the presence of a T3RE in
the first intron of the human NRGN. Alignment of the se-
quences of the human and rat introns (37) showed a high
degree of similarity in this region of the first intron, and
preliminary immunoprecipitation experiments similar to
those described above, but using the rat gene, suggested the
presence of a T3RE in a similar position (not shown). To
further delineate the receptor binding sequence, DNase I
footprinting analysis were performed. The 260-bp BamHI-
EcoRV fragment was subcloned in pMosblue, labeled by PCR
in the lower strand, and used in the DNase I footprinting
assay. Incubation of the fragment with nuclear extracts from
HeLa cells expressing T3Ra and RXRa, plus increasing
amounts of DNase I (Fig. 2A) resulted in a major protected
sequence of 20 nucleotides. Control reactions performed in
the presence of BSA showed no protected sequence. Analysis
of the protected sequence shown in Fig. 2A reveals an im-
perfect direct repeat of the consensus half-site AGGTCA
separated by four nucleotides (GGATTAaatgAGGTAA).
To analyze whether the sequence identified in the first
intron as a putative T3RE was functional in vitro, trans-acti-
vation assays were performed (Fig. 2B). For this purpose,
either a 140-bp fragment from the NRGN first intron con-
taining the T3RE or a single copy of a double stranded oli-
gonucleotide (NRGN T3RE, as shown in Materials and Meth-
FIG. 2. A, DNase I footprinting analysis of the immunoprecipitated
260-bp fragment from the first intron of NRGN. Probe fragment was
labeled as described in Materials and Methods. The resulting 260-bp
fragment, labeled by PCR on the lower strand, was purified with the
QIAquick PCR Purification Kit (Qiagen) and then incubated with
either vaccinia virus-expressed T3R/RXRa proteins or 6 mg BSA as a
control. The reactions were further digested with increasing amounts
of DNase I (1, 2, 3, and 6 mg/ml), the fragments were separated on an
8% sequencing gel, and the dried gel was autoradiographed for 36 h.
Simultaneously a G1A Maxam-Gilbert reaction was performed (not
shown). B, The NRGN oligonucleotide confers T3-dependent regula-
tion when inserted upstream of the thymidine kinase or the NRGN
promoter. The upper panel shows activation of the thymidine kinase
promoter (tk) by T3 through the Moloney murine leukemia virus T3RE
(Mo), the NRGN T3RE, or a 140-bp genomic fragment containing the
T3RE NRGN sequence. The lower panel shows activation of the NRGN
promoter (0.6-CAT construct, containing nucleotides 2513 to 176 of
the NRGN gene) by the Mo or NRGN T3REs. COS-7 cells were co-
transfected with the promoter constructs shown together with T3R
and RXR expression plasmids, and CAT activity was assayed 24 h
after the addition of T3 to a concentration of 150 nM or solvent.
338 NRGN IS A DIRECT TARGET OF THYROID HORMONE IN HUMAN BRAIN Endo • 1999
Vol 140 • No 1
 by on May 13, 2010 endo.endojournals.orgDownloaded from 
ods) was cloned upstream from the thymidine kinase
promoter in the pBLCAT-2 vector (140-tk-CAT or NRGN-
tk-CAT, respectively). COS-7 cells were cotransfected with
either of these two constructs together with expression vec-
tors encoding T3R and RXR. For comparison, cells were sim-
ilarly cotransfected with the CAT expression vector contain-
ing a single copy of the strong T3RE present in the Moloney
murine leukemia virus long terminal repeat, a prototypical
DR4 (Mo-tk-CAT). CAT activity was measured after incu-
bating the cells in the absence or presence of T3. The cells
transfected with either NRGN construct responded to the
addition of T3 with an increased CAT activity (Fig. 2B, upper
panel). In addition, we checked whether the T3RE was able to
confer regulation in the context of the NRGN promoter. For
this purpose, either the Moloney DR4 or the NRGN T3RE was
inserted upstream of the NRGN promoter in the promoter-
less pBLCAT-3 vector (Mo-0.6-CAT and NRGN-0.6-CAT, re-
spectively). In both constructs the addition of T3 increased
CAT activity, whereas it did not when the 0.6-CAT construct
without a T3RE was used as the control (Fig. 2B, lower panel).
Interaction of the thyroid hormone receptor with the
NRGN T3RE
A set of experiments was designed to characterize the
interaction of T3R in vitro with the NRGN T3RE by EMSA,
using in vitro translated T3Rb and RXRa, and labeled oligo-
nucleotides. For comparison, we also used the Moloney T3RE
(Fig. 3A). When labeled NRGN T3RE oligonucleotide was
incubated with human T3Rb and RXRa (lane 2), a retarded
band was observed showing the same mobility shift than the
RXR-T3R heterodimer obtained with the Mo T3RE (lane 1).
Neither T3R (lanes 6 and 8) nor RXR (lane 9) alone bound the
T3RE. The specificity of receptor binding was determined by
the addition of an excess of unlabeled competitors. The ad-
dition of Mo and NRGN oligonucleotides (lanes 3 and 5)
completely avoided formation of the retarded band. The
complex was not competed, however, when incubated in the
presence of a random DNA sequence (lane 4). Further proof
of the binding of T3R to the NRGN oligonucleotide was
obtained in supershift experiments, as shown in Fig. 3B. In
these experiments, the same shifted band was produced with
T3R/RXR plus either Mo (lane 10) or NRGN (lane 12) oli-
gonucleotides. The NRGN band was supershifted by addi-
tion of an anti-T3R antibody to the incubation mixture (lane
11), whereas the antibody alone was without effect (lane 13).
These experiments suggested that the NRGN T3RE bound
the RXR-T3R heterodimer and had no affinity for either T3R
monomer or homodimer.
To determine the relative binding strength of RXR-T3R
heterodimer to NRGN T3RE compared with that of the Mo
FIG. 3. Band shift assay demonstrating the binding of RXR-T3R heterodimer to the putative T3RE NRGN. A, Labeled oligonucleotides
representing the NRGN T3RE (NRGN) and the DR4 thyroid hormone-responsive element of the Moloney murine leukemia virus (Mo) were
incubated with in vitro translated T3Rb and RXRa. Both elements were capable of forming a RXR-T3R heterodimer shift (lanes 1, 2, and 7).
Competition assays were performed with a 200-fold molar excess of the indicated unlabeled oligonucleotides: Mo, NS (nonspecific sequence),
and NRGN (lanes 3, 4, and 5, respectively). Incubation with T3R alone (lanes 6 and 8) or RXR alone (lane 9) did not result in any retarded band.
B, The presence of T3R in the protein-DNA complex was demonstrated by the addition of an anti-T3R antibody to the reaction (lane 11). The
asterisk indicates the complex supershifted with the anti-T3R antibody. Addition of antibody alone (lane 13) or unprogrammed reticulocyte lysate
(lane 14) did not produce any shifted band.
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T3RE, we measured the time course of dissociation of the
preformed complex after adding a homologous oligonucle-
otide as a competitor (Fig. 4). These experiments were per-
formed in the presence or absence of Mg21 (35). In the ab-
sence of Mg21, the complex formed on the Mo T3RE was very
stable, with almost no dissociation after 45 min, a period
during which about 20% of the NRGN-receptor complex was
dissociated. In the presence of Mg21, the half-life of the Mo
complex was about 5 min, and that of the NRGN complex
was 2 min.
Role of each T3RE half site for binding the RXR-T3R
heterodimer
To evaluate the contribution of each NRGN T3RE half-site
to the binding of the RXR-T3R heterodimer, different muta-
tions in each half-site as well as in the spacer sequence were
introduced (Fig. 5A). The oligonucleotides were labeled and
incubated with receptors in the presence or absence of the
homologous unlabeled oligonucleotide in a molar excess to
determine the specificity of the retarded complex (Fig. 5B).
The substitution of two thymidines for two guanines in the
first half-site (M1) reduced the ability to bind the receptors.
The same mutation in the second half-site (M2) completely
suppressed the formation of the retarded band. Exchange of
the wild-type spacer sequence for another functional se-
quence, CTTA (M3) (38), produced a similar retarded band
as with the NRGN oligonucleotide. In Fig. 5C, the labeled
NRGN oligonucleotide was incubated with increasing
amounts of competing oligonucleotides, such as the wild-
type sequence; the mutants M1, M2, and M3; and a nonspe-
cific sequence (NS). Consistent with the results shown in Fig.
5B, when the wild-type sequence and that with the mutated
spacer (M3) were used, a small excess of cold oligonucleotide
strongly decreased the labeled DNA-protein complex,
whereas a nonspecific sequence had no competitor activity.
Modification of the first half-site (M1) decreased the com-
peting effect, but did not obliterate it completely. In contrast,
when the second half-site was modified (M2), the competing
effect of the oligonucleotide was completely lost. These re-
sults suggest that the integrity of the second half-site is es-
sential for binding the RXR-T3R heterodimer.
Discussion
Control of the RC3 gene might be an important feature of
thyroid hormone action in the brain, not only during the
critical developmental stages, but also in adult animals (15,
17). RC3 has been shown to be under thyroid control in rats
and goats, but it is not known whether the human RC3
homolog, NRGN, is under similar control in humans. Several
genes have been reported to be regulated by thyroid hor-
mone in some species but not in others, such as pituitary GH,
which is under control by T3 in rats but not in humans (39).
Considering the severe consequences of thyroid hormone
deprivation on human brain development and function (40–
FIG. 4. Off-rate experiments. In vitro translated TRb and RXRa were incubated with T3RE NRGN (upper panel) or Mo T3RE (lower panel)
labeled oligonucleotides, and a further 200-fold excess of the homologous unlabeled oligonucleotides was added. Aliquots of the incubation
mixture were loaded onto a running nondenaturing polyacrylamide gel at 0, 1, 2, 5, 15, 30, and 45 min. The complexes were quantified with
a phosphorimager and plotted. E, Mg21 binding buffer; F, EDTA binding buffer.
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42), it is important to identify what genes from those found
to be regulated in the rat are also regulated by thyroid hor-
mone in the human. Moreover, the RC3 gene is of great
interest because its control by thyroid hormone is reversible,
even in adult animals. Therefore, if regulated in humans, it
might be responsible for some of the effects of hypothyroid-
ism on mental states, such as impaired ability to learn and
memory loss. In this respect, even mild deficiencies of thy-
roid hormones, such as those present in subclinical hypo-
thyroidism, are often accompanied by impaired memory
(43). As RC3/NRGN is involved in postsynaptic mechanisms
leading to various forms of synaptic plasticity, it is tempting
to postulate that an impaired control of NRGN expression
might underlay some of these symptoms.
The presence of a T3RE in the first intron of the gene, as
shown here, strongly suggests that NRGN is a target of thy-
roid hormone in the human brain. The T3RE was localized
using a previously described technique that allowed the iso-
lation of T3 target genes from genomic libraries (34, 44).
Further characterization of the T3RE sequence was carried
out by footprinting, EMSA, and trans-activation analysis. The
footprinted sequence from NRGN contains an imperfect DR4
sequence (ggGGATTAaatgAGGTAA), with the second half-
site almost identical to the consensus sequence. It binds the
RXR-T3R heterodimer, but not T3R monomers or dimers, as
with other DR4 sequences that contain guanosine in the
spacer sequence between the half-sites and lack TC or TA
motifs upstream of the first half-site (25). The half-life of the
complex is similar to that of the strong T3RE present in the
Moloney virus terminal repeat, and the protein complex
shifted in the EMSA experiments was supershifted with an
anti-T3R antibody. Mutations of the two half-sites revealed
the requirement for the integrity of the second half-site to
bind the complex, in agreement with the known polarity of
the RXR-T3R heterodimer binding to DNA. Current models
suggest that T3R binds first to the distal half-site, and sub-
sequent binding of RXR increases binding affinity (45, 46).
Interestingly, NRGN T3RE is located in the first intron of
the gene, and preliminary data from our laboratory suggest
that a T3R-binding site is located in a similar position in the
first intron of the rat RC3 gene, in a conserved region of the
intron showing a high degree of similarity to the human
gene. Although most of the reported T3REs are located in the
upstream promoter region of the target genes, T3REs in in-
tronic locations have also been described, such as in the rat
GH gene, NCAM, and Pcp2 (39, 47, 48). Among the thyroid
hormone-dependent genes in brain only a few of them have
been shown to contain T3REs. These include myelin basic
protein (49), NCAM (47), tubulin (47), Pcp2 (48), and PGD2
synthase (50). NRGN is the second human brain gene, after
PGD2 synthase (51), in which a T3RE has been identified.
Previous studies in the rat have shown that the control
exerted by thyroid hormone on RC3 expression is region
specific (16). Some neuronal populations were sensitive,
whereas others insensitive to the effects produced by either
thyroid hormone deprivation or supplementation. The sen-
sitive regions were layer 6 of the cerebral cortex, layers 2–3
of retrosplenial cortex, the lateral caudate, and the granular
layer of the hippocampus. The insensitive regions included,
among others, the upper layers of cerebral cortex, the pyra-
FIG. 5. Analysis of the contribution of each half-site of the T3RE NRGN to the binding of the RXR/T3R heterodimer. A, T3RE NRGN wild-type
(NRGN) and mutant (M1, M2, and M3) sequences used in these studies. The T3RE half-sites are indicated by the arrows, and the positions
of the mutations are marked. B, The four oligonucleotides were labeled and incubated with in vitro translated T3Rb and RXRa, and the complexes
formed were resolved in a nondenaturing polyacrylamide gel. The specificity of the shifts was assessed by competition with a molar excess of
the unlabeled homologous oligonucleotides. C, EMSA with the oligonucleotide containing the T3RE NRGN sequence as probe. Competitors
correspond to the T3RE NRGN, M1, M2, and M3 and a nonspecific sequence (NS) at the indicated fold molar excess.
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midal layers of the hippocampus, and the amygdala. The fact
that RC3 expression is modulated by thyroid hormone in
specific regions suggested that the T3 control was indirect, so
that RC3 could be a distal response subsequent to activation
of an earlier responsive gene. However, as pointed out above,
T3 induces RC3 expression in cultured cells at the transcrip-
tional level and does not require protein synthesis (21). The
finding of a T3RE in NRGN provides further support for a
direct interaction of thyroid hormone receptors with regu-
latory sequences in this gene. Therefore, the reasons for dif-
ferential T3 sensitivity remain to be determined. We have
previously discarded the idea that this phenomenon is due
to differential expression of thyroid hormone receptor iso-
forms (36). Other possibilities to be explored are differential
expression of T3R coregulators or an effect due to chromatin
conformation.
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